Belantamab Mafodotin shows significant OS benefit, reducing the risk of death by 42% in multiple myeloma at or after first ...

GSK (NYSE:GSK) reported that a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in ...

GSK (GSK) reported a study showed its drug belantamab mafodotin was able to reduce the risk of death by 42% in certain ...

智通财经APP获悉，葛兰素史克 (GSK.US)报告称，一项研究表明，其药物 belantamab mafodotin 能够将多发性骨髓瘤患者在首次复发时或复发后的死亡风险降低 42%。

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the ...

Capivasertib combination shows promise in mHSPC vs the placebo combination, LBS-007 received fast track designation, and RP1 plus nivolumab submitted a BLA application. We also cover a retrospective ...

A trial has shown that belantamab mafodotin can reduce the risk of death by 42% in patients with relapsed or refractory ...

GSK plc (NYSE:GSK) announced statistically significant and clinically meaningful overall survival (OS) results from a planned ...

今日（12月6日），中国国家药监局药品审评中心（CDE）官网最新公示显示，葛兰素史克（GSK）申报的注射用玛贝兰妥单抗上市申请获得受理。公开资料显示，这是GSK在研的Blenrep（belantamab ...

Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...

The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...